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Abstract 22 
A large proportion of cardiovascular pathology results from immune-mediated damage, including 23 
systemic inflammation and cellular proliferation, which cause a narrowing of the blood vessels. Expansions 24 
of cytotoxic CD4+ T-cells characterized by loss of CD28 (‘CD4+CD28− T-cells’ or ‘CD4+CD28null cells’) are 25 
closely associated with cardiovascular disease (CVD), in particular coronary artery damage. Direct 26 
involvement of these cells in damaging the vasculature has been demonstrated repeatedly. Moreover, 27 
CD4+CD28− T-cells are significantly increased in rheumatoid arthritis (RA) and other autoimmune 28 
conditions. It is striking that expansions of this subset beyond 1-2% occur exclusively in CMV-infected 29 
people. CMV infection itself is known to increase the severity of autoimmune diseases, in particular RA and 30 
has also been linked to increased vascular pathology. A review of the recent literature on immunological 31 
changes in cardiovascular disease, RA, and CMV infection provides strong evidence that expansions of 32 
cytotoxic CD4+CD28− T-cells in RA and other chronic inflammatory conditions are limited to CMV-infected 33 
patients and driven by CMV-infection. They are likely to be responsible for the excess cardiovascular 34 
mortality observed in these situations. The CD4+CD28− phenotype convincingly links CMV infection to 35 
cardiovascular mortality based on a direct cellular-pathological mechanism rather than epidemiological 36 
association. (193 words) 37 
  38 
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Introduction 39 
CD28 is a co-stimulatory molecule expressed on naïve CD4+ and CD8+ T-cells. A permanent loss of 40 
CD28 occurs during antigen-driven differentiation towards a terminal phenotype. Its loss suggests that co-41 
stimulation by antigen-presenting cells via its specific ligands B7.1 (CD80) and B7.2 (CD86) is no longer 42 
required and is indicative of replicative senescence.(Vallejo et al., 1999) This should not be confused with 43 
the transient loss of CD28 expression on CD4+ (and CD8+) T-cells during proliferation, which is reversible 44 
within days.(Vallejo et al., 1999)  45 
CD4+CD28− T-cells were first identified in the plaques of patients with unstable angina but since 46 
then, expansions of these cells have been reported in a range of cardiovascular (CV) conditions. They 47 
attracted particular interest in acute coronary syndrome (ACS) and myocardial infarction where their 48 
presence was associated with increased acute mortality and recurrence.(Liuzzo et al., 1999; Liuzzo et al., 49 
2000; Liuzzo et al., 2007) Patients with CD4+CD28− T-cell expansions also showed preclinical 50 
atherosclerotic changes.(Gerli et al., 2004) A recent study of ACS with/without diabetes mellitus (DM) 51 
reported the highest frequencies of CD4+CD28− T-cells when both conditions were present, followed by 52 
ACS only, DM only, and finally controls.(Giubilato et al., 2011) 53 
As regards autoimmune diseases, expansions of so-called ‘CD4+CD28null’ (synonymous for 54 
CD4+CD28−) were described in RA patients almost 20 years ago.(Martens et al., 1997) Their limited TCR Vβ 55 
chain usage suggested restricted antigen-specificity and potential involvement in autoimmunity; 56 
interestingly, their numbers were related to the extent of extra-articular involvement.(Schmidt et al., 1996a; 57 
Schmidt et al., 1996b; Martens et al., 1997) Over the years, CD4+CD28− T-cells have been shown to be 58 
implicated in various inflammatory conditions (Dumitriu, 2015) including Granulomatosis with polyangitis 59 
(GPA), where CD4+CD28− T-cells were linked to increased infection and mortality.(Morgan et al., 2011) 60 
Table 1 provides a list of conditions in which a role of CD4+CD28− T-cells was reported or investigated. 61 
 62 
CMV infection triggers the expansion of CD4+CD28− T-cells 63 
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There is a striking link between CD4+CD28− T-cells and CMV infection. Work in renal 64 
transplantation has demonstrated that the emergence and expansion of CD4+CD28− T-cells in CMV-65 
seronegative (CMV−) graft recipients directly results from infection by a CMV-seropositive (CMV+) graft. 66 
Recipients showed detectable levels of CD4+CD28− T-cells just after the clearance of CMV viral load and the 67 
proliferation of these cells in vitro could be stimulated by CMV antigen but not tuberculin or tetanus toxoid, 68 
for example. However, CD4+CD28− T-cells did not emerge in CMV− recipients of CMV− grafts.(van Leeuwen 69 
et al., 2004) Furthermore, CMV-specific CD4+ T-cells are in large part CD28−.(Akbar and Fletcher, 2005) 70 
Given that ex-vivo T-cell stimulation cannot adequately cover all CMV-antigens, it has remained unclear if 71 
all CD4+CD28− T-cells are CMV-specific or if some of them expand after CMV infection for reasons yet to be 72 
discovered. Interestingly, Zal et al. reported that in patients with ACS and/or chronic stable angina (CSA) 73 
CD4+CD28− T-cells (partially) responded to HSP60 but not to a CMV lysate.(Zal et al., 2004) It is important 74 
to note, however, that CMV-lysates (prepared from lytically CMV-infected human fibroblasts) are not an 75 
all-inclusive collection of CMV-antigens.(Sylwester et al., 2005) It is possible, therefore, that CD4+CD28− T-76 
cells specific for antigens not represented in the lysate cross-reacted with HSP60. Cross-reactivity between 77 
HSP60 and the CMV UL122 and US28 proteins has indeed been described for antibodies, which might be an 78 
indirect mechanism by which CMV infection facilitates endothelial cell injury.(Bason et al., 2003)  79 
Strikingly, not a single study has reported accumulations of CD4+CD28− T-cells in CMV-uninfected 80 
individuals; however, some studies have reported low frequencies of these cells in CMV− people in the 81 
order of 1-2% of CD4 T-cells.(Morgan et al., 2011) Of note, in the context of inflammatory diseases such as 82 
rheumatoid arthritis (RA) and GPA, CMV-driven expansions of CD4+CD28− T-cells are accentuated 83 
compared to otherwise healthy individuals, which will increase the potential for tissue damage.(Thewissen 84 
et al., 2007b; Morgan et al., 2011) Based on the literature we have drafted a model of CMV antigen-driven 85 
T-cell differentiation towards the emergence of CD4+CD28− T-cells (Figure 1). This pathway is different 86 
from pathways leading to T-cell exhaustion, which are typically associated with a loss of effector 87 
functions.(Wherry and Kurachi, 2015)  88 
 89 
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CD4+CD28− T-cells are terminally differentiated effector cells 90 
Before CD4+ T-cells lose CD28 expression they will have lost the expression of a number of other 91 
molecules, in particular the costimulatory receptor, CD27, and gained expression of memory markers. 92 
(Appay et al., 2008) Unlike normal helper T-cells, CD4+CD28− T-cells do not provide help to B-cells, however, 93 
they express NK-cell receptors, in particular killer activating receptors (KAR).(Namekawa et al., 1998; 94 
Namekawa et al., 2000; Fasth et al., 2010) They produce more TNF-α and IFN-ɣ and are more cytotoxic than 95 
CD4+CD28+ T-cells.(Appay et al., 2002; Teo et al., 2013) CD4+CD28− T-cells may home to atheromatous 96 
lesions because they express the chemokine receptors, CXCR3, CCR6 and CCR7.(Teo et al., 2013; Pieper et 97 
al., 2014) Of note, vascular EC are primary CMV infection targets.(Ho et al., 1984) Synovial fluid CD4+CD28− 98 
T-cells from RA patients produce less IFN-ɣ and TNF-α than their circulating counterparts and, unlike them, 99 
also produce IL-17A.(Pieper et al., 2014) Additionally, they produce perforin and granzyme B, which can 100 
destroy synovial tissue.(Appay et al., 2002; Komocsi et al., 2002; Davis et al., 2013) Reduced responsiveness 101 
to CD4+CD25+ regulatory T-cells and resistance to apoptosis further add to their destructive 102 
potential.(Tsaknaridis et al., 2003; Thewissen et al., 2007a) Table 2 lists the most prominent features of 103 
CD4+CD28− T-cells.  104 
 105 
CMV involvement in cardiovascular disease - clinical observations and epidemiology 106 
CMV infection has been associated with vascular pathology ever since the virus was isolated from 107 
atherosclerotic lesions, but it was unclear if it played a causative role.(Degre, 2002) To date there is strong 108 
epidemiologic evidence that CMV is the major driver of premature CV disease (CVD) in HIV infected 109 
people(Aiello and Simanek, 2012) and increasing recognition of an association with higher CVD mortality in 110 
HIV-uninfected people.(Simanek et al., 2011) Meanwhile, a role for CMV in driving/accelerating 111 
autoimmune disease has been the subject of discussion since the early 1990s.(Halenius and Hengel, 2014) 112 
Of particular interest to this review, several authors have shown that CMV infection exacerbates 113 
inflammation in RA,(Tan et al., 2000; Morgan et al., 2011; Pierer et al., 2012; Quandt et al., 2014) with one 114 
study indicating that higher anti-CMV antibody levels associate with more frequent surgical procedures and 115 
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more severe joint damage.(Pierer et al., 2012) Several authors have shown that in RA patients CMV 116 
antigens are indeed detectable in synovial tissue.(Einsele et al., 1992; Murayama et al., 1992) Also, high 117 
numbers of virus-specific T-cells including CMV-specific T-cells can be found at these sites.(Tan et al., 2000) 118 
Table 3 shows cardiovascular and autoimmune conditions in which CMV has been implicated. 119 
There are several epidemiological links between CMV infection and CVD. In particular, lower socio-120 
economic position (SEP) correlates with a higher prevalence of dyslipidaemia, higher cholesterol, and 121 
smoking, which are all risk factors for CVD. However, lower SEP is also associated with a high prevalence of 122 
CMV infection.(Dowd et al., 2009) Therefore, CVD and CMV are significantly correlated at an 123 
epidemiological level in such populations, which complicates the analysis. A recent cross sectional study, 124 
however, found that despite this complex interrelatedness of risk factors, CMV infection may explain partly 125 
the relationship between SEP and cardiovascular disease.(Simanek et al., 2009) There is also 126 
epidemiological evidence that CMV is a driver of heart disease in HIV+ women.(Parrinello et al., 2012) The 127 
complexity and importance of this issue was recently highlighted.(Aiello and Simanek, 2012)  128 
 129 
Evidence linking (CMV-specific) T-cells to hypertension, vascular pathology and acute coronary events 130 
The evidence for a role of T-cells in myocardial infarction has recently been reviewed identifying 131 
direct involvement of CD4+ and CD8+ T-cells in both coronary artery injury and healing/remodeling with 132 
regulatory T-cells being particularly involved in the latter.(Hofmann and Frantz, 2016)  133 
Following CMV infection of EC, class-II MHC expression in these cells is reduced hampering CMV-134 
antigen presentation to CD4+ T-cells.(Sedmak et al., 1994) However, CMV-infected EC can release non-135 
infectious exosomes (NIE) that are replete with CMV proteins, in particular UL55, a major CD4+ T-cell target 136 
protein. Uptake of NIE by APCs leads to effective presentation of CMV antigens to CD4+ T-cells.(Walker et 137 
al., 2009) Moreover, pro-inflammatory mediators released by PBMCs in response to CMV can induce 138 
expression of Fractalkine (FKN) and IP-10 in EC. These specifically bind the chemokine receptors CX3CR1 139 
and CX3CR3, respectively, which are expressed on effector CD4+ and CD8+ T-cells in CMV-infected 140 
individuals.(van de Berg et al., 2012) We hypothesize that vasculature-infiltrating CD4+CD28− effector T-141 
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cells expressing CX3CR1 and/or CX3CR3 are, therefore, attracted to FKN and IP-10-producing EC. Cytotoxic 142 
molecules secreted by CD28− T-cells (Table 2) may then trigger EC death by apoptosis. Of interest, CMV 143 
immune evasion includes down-regulation of class-I MHC expression on infected EC but leaves HLA-E 144 
expression unaffected. NKG2C+ expressing NK-cells and T-cells expand in CMV infection and NKG2C+ 145 
mediated cytotoxicity is triggered by the interaction between CD94/NKG2C and HLA-E molecules on CMV-146 
infected EC.(Almehmadi et al., 2014; Djaoud et al., 2016) Figure 2 provides a synopsis of these mechanisms. 147 
Work in mouse models has also confirmed a role for T-cells in hypertension, an important 148 
contributor to vascular damage; RAG-1 double-knockout (RAG-1 -/-) mice) lacking both T-cells and B-cells 149 
showed blunted hypertension in response to angiotensin-II infusion or (DOCA)-salt. They also exhibited 150 
decreased vascular reactive oxygen species (ROS) production with reduced consumption of the relaxing 151 
factor, nitric oxide (NO). Adoptive transfer of T-cells (but not B-cells) restored these effects to 152 
normal.(Guzik et al., 2007) Others showed that murine CMV (MCMV) infection leads to hypertension within 153 
weeks independently of atherosclerotic plaque formation, but at the same time contributes to (aortic) 154 
atherosclerosis, which might result from persistent CMV infection of EC inducing renin expression.(Cheng 155 
et al., 2009) This will in turn increase local angiotensin-II levels, which might activate angiotensin-II receptor 156 
positive infiltrating T-cells to produce more ROS. Recently, Pachnio et al.(Pachnio et al., 2016) have 157 
confirmed that CMV-induced CD4+CD28− T-cells indeed have all the necessary properties required to 158 
infiltrate the vasculature.  159 
 160 
Rheumatoid arthritis and cardiovascular complications 161 
As a result of an excess of CV events, the life expectancy of RA patients is reduced by 3-10 years 162 
compared with the general population.(Kaplan, 2010; Amaya-Amaya et al., 2013) The risk of CVD-163 
associated death is up to 50% higher in RA patients than controls and the risks of ischemic heart and 164 
cerebrovascular diseases are elevated to a similar extent.(Avina-Zubieta et al., 2008) RA is the most 165 
common inflammatory joint disease worldwide, affecting about 1 % of the population.(Amaya-Amaya et al., 166 
2013) RA is characterised by infiltration of the synovial membranes by pro-inflammatory immune cells, 167 
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swelling and deformity of joints and excess synovial fluid containing infiltrating immune cells and 168 
cytokines.(Libby, 2008; Waldele et al., 2015) Extra-articular manifestations are widespread and involve the 169 
CV system.(Maradit-Kremers et al., 2005)  170 
Traditional CVD risk factors such as smoking, physical inactivity, hypertension and diabetes mellitus 171 
contribute to death from CVD in RA but do not have the same predictive value as in patients without 172 
RA.(Gabriel, 2008; Amaya-Amaya et al., 2013) There is some evidence that RA itself accelerates 173 
atherogenesis.(del Rincon et al., 2001) Also, following myocardial infarction patients with RA have 174 
considerably higher 30-day case fatality rates.(Kaplan, 2010) Chronic inflammation is a normal consequence 175 
of ageing(Franceschi et al., 2000) and a key player in atherogenesis. It promotes endothelial cell activation 176 
and vascular dysfunction and, together with other risk factors, leads to arterial wall thickening, promotes 177 
atheromatous changes, induces decreased vascular compliance, and contributes to increased blood 178 
pressure. This further promotes vascular damage in a self-perpetuating cycle. Ultimately, blockage of blood 179 
vessels may lead to myocardial infarction or stroke.(Hansson, 2005; Kaplan, 2010) 180 
 181 
CD4+CD28− T-cells arise as an obvious mechanistic link between CMV-infection, CVD, and RA  182 
The vast majority of studies investigating the presence and role of CD4+CD28− T-cells in CVD and 183 
autoimmune diseases did so without considering participant CMV infection status, suggesting that many 184 
researchers are unaware of the association of an expansion of this subset with CMV infection. The most 185 
relevant details from a number of such reports are found in Supplementary Table 1 and Supplementary 186 
Table 2. Only a handful of studies explored the presence of CD4+CD28− and/or CD8+CD28− T-cells in CVD 187 
or autoimmune disease in the context of CMV infection status. Interestingly, most of these included CMV+ 188 
participants only. We identified only two studies that included CMV+ and CMV− participants (Table 4). 189 
Among the studies not accounting for CMV status, several reported significant differences between RA 190 
patients and healthy controls with respect to the frequency of CD4+CD28− T-cells.(Schmidt et al., 1996a; 191 
Gerli et al., 2004; Bryl et al., 2005; Thewissen et al., 2007b) Also, major differences were reported between 192 
cases with limited RA and extra-articular RA.(Michel et al., 2007) On the whole, between 3 to 10 times 193 
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more CD4+CD28− T-cells were reported in RA compared to healthy controls. With respect to CVD, Liuzzo et 194 
al. found 9-fold higher levels of CD4+CD28− T-cells in patients with unstable angina compared to those with 195 
stable angina; these differences were later confirmed in a second study.(Liuzzo et al., 1999; Liuzzo et al., 196 
2000) Rizello et al., by contrast, found ‘only’ a 2.5 fold difference in CD4+CD28− T-cell levels between such 197 
groups (Rizzello et al., 2006). Others reported frequencies of CD4+CD28− lymphocytes (rather than T-cells) 198 
as a percentage of all lymphocytes, which makes their data difficult to compare.(Teo et al., 2013)  199 
Reports in GPA and RA patients clearly confirm that significant expansions of the CD4+CD28− T-cell 200 
subset only occur in CMV+ individuals. The levels of these cells were 24-fold higher and 22-fold higher in 201 
CMV+ compared with CMV− GPA and RA patients, respectively.(Morgan et al., 2011; Pierer et al., 2012) 202 
Also, the relative expansions in CMV+ compared to CMV− individuals were significantly accelerated in the 203 
presence of GPA as they were increased ‘only’ by factor 14 higher in healthy controls. The remaining 204 
studies listed in Table 4 report CD4+CD28− T-cell frequencies in CMV+ individuals only.  205 
In summary, the listed reports argue strongly in favour of a role of CMV infection in CV 206 
complications, most likely as a result of the distribution of the CD4+CD28− subsets in the disease and 207 
control groups. 208 
 209 
Could CD4+CD28− T-cells be targeted by immunotherapies? 210 
Experimental evidence suggests that anti-CMV treatment could reduce the reactivity as well as the 211 
numbers of CMV-specific T-cells. Particularly, low dose acyclovir (ACV) therapy decreases the CD4+ T-cells 212 
response to pp65 CMV protein, most likely by diminishing the CMV-antigen load, turnover, and uptake by 213 
APCs.(Pachnio et al., 2015) In addition there is evidence from mouse models that, at least in older mice, 214 
valaciclovir treatment leads to an 80% reduction of the CD8+ T-cell response to MCMV.(Beswick et al., 2013) 215 
If CMV-specific T-cells were actually involved in mediating CMV-driven vascular damage, then a possible 216 
approach to slow down this process would be the use of anti-viral drugs.  217 
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Therapies based on the direct targeting of CD4+CD28− T-cells have been investigated in several 218 
conditions. To this regard, the effects of different therapeutic regimens on CD4+CD28− T-cell frequencies 219 
have been investigated in patients with hyperinsulinemic polycystic ovary syndrome, in which increased 220 
frequencies of this subset have also been observed (but an association with CMV has not been 221 
investigated). Treatment with Drospirenone–Ethinylestradiol and Metformin resulted in a significant 222 
reduction of frequencies of CD4+CD28− T-cells.(Moro et al., 2013) Moreover, it has been demonstrated in 223 
organ transplant recipients that treatment with polyclonal anti-thymocyte globulin (ATG) preferentially 224 
triggers apoptosis in CD4+CD28− compared to CD4+CD28+ T-cells (Duftner et al., 2012). Other therapies 225 
targeting the functional capacity of these cytotoxic cells have been investigated as well. The only K+ 226 
channels present in CD4+CD28− T-cells from ACS patients are Kv1.3 and IKCa1. Blockade of the Kv1.3 227 
channel by 5-(4-Phenoxybutoxy)psoralen (PAP-1) resulted in suppression of the pro-inflammatory function 228 
of CD4+CD28− T-cells (Xu et al., 2012), however, did not appear to induce general immunosuppression. In a 229 
rat model, chronic administration of PAP-1 prevented the development of unstable atherosclerotic plaques, 230 
most probably by blocking the release of inflammatory and cytotoxic molecules from CD4+CD28− T 231 
cells.(Wu et al., 2015) Finally, in RA patients treated with Abatacept (ABA), a reduction of circulating 232 
CD4+CD28− T-cells has been observed and it was correlated with a reduction of disease activity.(Scarsi et al., 233 
2011; Airo and Scarsi, 2013; Imberti et al., 2015) Similar results were observed by Pierer et al (Pierer et al., 234 
2011) in RA patients treated with TNF-α blocking agents (etanercept and infliximab). Anti-TNF therapy has 235 
been shown to diminish the myocardial infarction risk and to increase vascular compliance (Dixon et al., 236 
2007; Barnabe et al., 2011). At the same time it reduces the number of CD4+CD28− T-cells.(Rizzello et al., 237 
2006) However, little is known about how other drugs used in RA affect CV complications (recently 238 
reviewed in this journal).(Mason and Libby, 2015) 239 
 240 
Conclusions 241 
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We believe that the literature reviewed in this article explains to a large extent the striking 242 
epidemiological association reported between CMV infection and increased cardiovascular 243 
mortality.(Guech-Ongey et al., 2006; Wang et al., 2010; Simanek et al., 2011; Savva et al., 2013; Tracy et al., 244 
2013; Spyridopoulos et al., 2015) It is, in particular, the emerging, immediate and specific role of 245 
CD4+CD28− T-cells in both acute and chronic vascular pathology that takes this association to a higher level. 246 
This is, because expansion of this T-cell subset beyond a very small percentage (1-2% of CD4+ T-cells) is 247 
exclusively found in CMV+ individuals. Literature from the fields of chronic inflammation/autoimmunity, 248 
cardiovascular disease, and viral immunology, together provide a fascinating insight into the effects of 249 
expanded populations of cytotoxic, CD4+CD28− T-cells. These are ultimately driven by a common virus 250 
infection, whose burden on the immune system is still being underestimated.(Manicklal et al., 2013)  251 
252 
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Figure legends 253 
Figure 1. T-cell differentiation and the emergence of CMV-induced T-cell phenotypes. Memory T-cell 254 
differentiation is regulated by intracellular and extracellular factors. Mechanisms of memory development 255 
upon naïve T-cell activation (antigen stimulation) are the subject of on-going discussion. Since it has been 256 
reported that CD4+ T-cell memory development resembles that of CD8+ T-cells,(Harrington et al., 2008) we 257 
assumed that both T-cell subsets follow similar pathways. However, transitional memory subsets sitting 258 
between central memory T-cells (TCM) and effector memory T-cells (TEM) have been described in the CD4+T-259 
cell compartment. Several memory T-cell subsets have been defined but their lineage relationship has 260 
remained unclear. Some models describe a linear origin of memory T-cells directly from effector T-cells; 261 
other models propose a divergent differentiation where naïve T-cells give rise to memory and effector T-262 
cells through asymmetrical division. More recently a progressive differentiation pathway has been 263 
proposed, depending on stimulus intensity and duration (represented inside the box). According to this 264 
model, T-cell fate depends on the duration of signalling and presence/absence of cytokines. Brief 265 
stimulation leads to the generation of TCM whereas sustained stimulation plus presence of cytokines 266 
generates TEM. Therefore, in the progressive model a single naïve T-cell will give rise to different memory T-267 
cell subsets that are the precursors of terminally differentiated effector T-cells. Progression into these 268 
differentiated memory subsets relies on the gradual response to cytokines, acquisition of tissue homing 269 
receptors, resistance to apoptosis and gain of effector functions while gradually losing lymph node homing 270 
receptors, proliferative capacity , and the ability to produce IL-2 production, to self-renew, and survive (For 271 
review: (Kaech et al., 2002; Ojdana et al., 2008; Ahmed et al., 2009; Farber et al., 2014; Flynn and Gorry, 272 
2014)). Although the exact origin of the CD28− T-cell phenotype is not clear, based on the literature we 273 
hypothesize that these cells arise from terminally differentiated effector memory T-cells (TEMRA) as well as 274 
TEM after exposure to CMV. Legend: Th = T-helper cell, CTL=Cytotoxic T-cell, TSCM=Stem Cell Memory T-cell, 275 
TCM= Central Memory T-cell, TEM =Effector Memory T-cell, TEMRA =terminally differentiated (CD45RA re-276 
expressing) Effector Memory T-cell. 277 
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Figure 2. Proposed mechanisms for CMV-driven vascular damage. CMV-infected EC will down-278 
regulate MHC expression but produce non-infectious exosomes (NIE) loaded with CMV-proteins, in 279 
particular UL55 (gB) [1],(Walker et al., 2009) allowing effective CMV antigen presentation by antigen-280 
presenting cells (APC) following NIE uptake/processing. Vasculature-infiltrating CMV-specific CD4+ effector 281 
T-cells will hence encounter these antigens on APC (shown as green CMV antigen in diagram; green block 282 
arrow) [2] and subsequently produce pro-inflammatory mediators such as IFN-. These induce the 283 
expression of Fractalkine (FKN), IFN- inducible protein 10 (IP-10) and possibly additional chemokines in EC 284 
[3],(van de Berg et al., 2012) which in turn attract infiltrating CD4+CD28− and probably also CD8+CD28− T-285 
cells to the ECs [4]. These may be CMV-specific but possibly also non-CMV-specific (symbolized by red 286 
‘target antigen’ in diagram; red block arrow). They may kill ECs through perforin/granzyme secretion [5]. 287 
Despite CMV infection, HLA-E expression remains unaffected in EC, so that interaction between HLA-E on 288 
EC and CD94/NKG2C on NK-cells may also trigger CD94/NKG2C-mediated cytotoxicity [6].(Djaoud et al., 289 
2016) NKG2C+ NK cells are known to be expanded by CMV infection and it is noteworthy that CD4+CD28− 290 
T-cells may also express NKG2C (indicated by “?” in diagram). Acyclovir reduces CMV-specific T-cell 291 
responses by inhibiting replication(Pachnio et al., 2015) and will probably reduce NIE formation in infected 292 
EC, thus reducing antigen presentation by APCs and subsequent effector T-cell activation [7].  293 
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Tables 295 
 296 
Table 1: Conditions in which CD4+CD28− T-cells were reported and/or investigated 297 
Cardiovascular 
(Liuzzo et al., 1999; Liuzzo et al., 
2000; Gerli et al., 2004; Brugaletta 
et al., 2006; Rizzello et al., 2006; 
Alber et al., 2009; Dumitriu et al., 
2009; Koller et al., 2013; Teo et al., 
2013) 
Autoimmune 
(Schmidt et al., 1996b; Namekawa et 
al., 1998; Namekawa et al., 2000; 
Gerli et al., 2004; Bryl et al., 2005; 
Michel et al., 2007; Thewissen et al., 
2007a; Fasth et al., 2010; Giubilato 
et al., 2011; Morgan et al., 2011; 
Pieper et al., 2014; Maly and 
Schirmer, 2015) 
Other 
(Shabir et al., 2016) 
Angina pectoris Rheumatoid arthritis Renal transplant dysfunction 
Acute coronary syndrome Granulomatosis with Polyangitis  
Myocardial infarction Diabetes  
Chronic heart failure Systemic Lupus Erythematosus  
abdominal aortic aneurysms Multiple Sclerosis  
 Ankylosing Spondylitis  
 Crohn’s Disease  
 Graves’ Disease  
 Autoimmune Myopathy  
 Dermatomyositis  
 Polymyositis  
 
Polymyalgia Rheumatica and 
Giant cell Arteritis 
 
 298 
 299 
  300 
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Table 2: Properties of CD4+CD28− T- cells 301 
Molecule type/property Specific molecules/properties identified 
(Weyand et al., 1998; Almehmadi et al., 2015; Maly and 
Schirmer, 2015) 
Costimulatory receptor CD27−, CD40L-, OX40+(CD134), 4-1BB+(CD137) 
Chemokine receptors CCR7−, CX3CR1+ (Fractalkine receptor), CCR5+ 
Toll-like receptors TLR2+, TLR4+ 
Natural Killer receptors KIR+, NKG2D+, CD11b+, CD161+, NKG2C+ 
Adherin/Integrin VLA-4+, ICAM-1+ 
Cytokines and mediators IFN-ɣ+, TNF-α+, IL-2+, Perforin+, Granzyme B+ 
Other features - increased resistance to apoptosis 
- increased resistance Treg suppression 
- Slow division rate (replicative senescence) 
 302 
  303 
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Table 3: Cardiovascular and autoimmune conditions in which a role of CMV infection has been suspected 304 
or confirmed. 305 
Cardiovascular 
(Nieto et al., 1996; Streblow et al., 2001; Bason et al., 
2003; Ji et al., 2012; Tracy et al., 2013) 
Autoimmune 
(Hjelmesaeth et al., 2004; Morgan et al., 2011; 
Soderberg-Naucler, 2012; Halenius and Hengel, 2014) 
Atherosclerosis 
Hypertension 
Coronary heart disease 
Rheumatoid arthritis 
Lupus Erythematosus 
Sjoegren’s syndrome 
Granulomatosis with Polyangitis  
Diabetes Mellitus  
Systemic Sclerosis 
 306 
 307 
 308 
  309 
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Table 4: CD4+CD28− T cells in studies stratified by CMV status 310 
Study (year) 
[ref] 
Disease 
Number of 
individuals 
in study 
M:F 
ratio 
Age range or 
IQR in years 
(median) 
and/or mean 
+/- STD 
Cell subset 
investigated 
% of reference subset 
given as mean or median 
or 
absolute counts/ul blood  
mean +/- STD  
      CMV+ CMV− 
Thewissen RA 4 1:3 59-76 (67) 
CD4+CD28− 
9.6 n.k. 
(2007)(Thewisse
n et al., 2007a) 
HC 4 3:1 30-48 (35) 9.3 n.k. 
Morgan GPAa 48 25:23 47-74 (64) 
CD4+CD28− 
19 0.8 
(2011) (Morgan 
et al., 2011) 
HCb 38 13:25 41-77 (57) 22 1.4 
Pierer 
RA 202 49 :153 51-68 (62) CD4+CD28− 8.15 0.37 (2012) (Pierer et 
al., 2012) 
 
CVD 43c All male 55.1 +/-5.6 
CD4+CD28− 6.7 
 CD8+CD28− 452+/-258 172+/-174 
Jonasson CD8+CD57+ 392+/-226 167+/-183 
(2003) 
(Jonasson et al., 
2003) HCb 69c All male 49.5 +/-5.9 
CD4+CD28− 5.8 
 CD8+CD28− 329+/-216 112+/-71 
 CD8+CD57+ 269+/-190 105+/-67 
 311 
n.k. = not known; aGPA Granulomatosis with Polyangiitis was used here as a comparative inflammatory disorder; bHC 312 
Healthy control; c67% of patients and 61% of controls were CMV+;  313 
 314 
 315 
 316 
  317 
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